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large polyps, natural history of adenoma transition to cancer and importantly, 
adherence. CTC was found to be cost-effective in three studies, assuming the most 
favourable scenario. ConClusions: CTC has the potential to be a cost-effective 
CRC screening strategy when compared to COL. There is a strong need for a differ-
ential consideration of patient adherence and compliance to CTC and COL. Recent 
research shows that laxative-free CTC screening has the potential to become a viable 
alternative screening method for CRC as it can improve patient uptake of screening. 
This project is supported by the German Federal Ministry of Education and Research 
(BMBF) as part of the National Cluster of Excellence‚ Medical Technologies – Medical 
Valley EMN’ (Project grant No. 13EX1013B).
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objeCtives: With tightening health system budgets, medical devices (MDs) are 
being increasingly scrutinized for their impact on overall health care cost. The evi-
dence bar for implantable MDs is particular high since most implantable devices 
are not reimbursed separately by payers, but via direct bundled payments to the 
provider. To characterize that trend, the objectives of this study were to: 1) Identify 
specific evidence criteria that maximally impact the payer decision, 2) Note differ-
ences in HTAs across global markets, and finally 3) Outline differences in evidence 
requirements between drugs and devices. Methods: A multimarket review of 
implantable MD HTAs and reimbursement decisions published from 2008-2013 was 
conducted. Identified by HTA Watch, HTAs included those from Australia, Belgium, 
Canada, France, Germany, Italy, the UK and the US. They spanned a variety of indi-
cations, including cardiovascular, orthopedic, neurological, trauma, among others. 
HTAs and reimbursement decisions were characterized for clinical and economic 
evidence requirements and apparent correlations and/or impacts on ultimate 
agency recommendation. Results: Evidence criteria evaluated by HTA agencies 
and payers primarily included: 1) Availability of supportive randomized controlled 
trials (RCTs), 2) Safety, 3) Efficacy/long-term outcomes, 4) Cost/cost-offsets/budget 
impact, and 5) Quality of-life improvement. In contrast to drug HTAs, clinician 
training and learning curve effects were often evaluated. Importantly, agencies 
recognized the challenge in demonstrating statistically- and clinically-significant 
evidence of improvement in outcomes. As such, many MDs were recommended 
on a restricted basis to specific patient subpopulations or on a coverage based 
on continued evidence development. While requirements considered most critical 
were largely uniform across global markets, regional nuances impacted the ability 
to obtain favorable reimbursement of implantable devices. ConClusions: Similar 
to drugs, MDs face rising hurdles in terms of demonstrating value, both clinical and 
economic. Optimal global market access for implantable MDs hinges on monitoring 
evolving evidentiary requirements and on carefully planning to collect evidence 
early in the developmental cycle.
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objeCtives: Coverage with evidence development (CED) is increasingly being 
used to provide provisional coverage for promising, but unproven, interventions, 
while additional data are generated. This study aimed to explore the application of 
CED in the context of devices. Methods: First, a literature review was conducted 
on international CED schemes and the CED approach more generally. In total, 50 
articles were gathered and reviewed. Second, semi-structured telephone inter-
views were conducted with different expert groups (payers/HTA bodies, industry, 
and academics/policy analysts) to better understand the use of CED in different 
jurisdictions; identify and explore device CED case studies; and, gather expert 
opinion on the challenges associated with the CED approach and potential strate-
gies to improve current policy and practice. A total of 25 experts were invited to 
participate, of which 20 (80%) agreed and were interviewed. Results: Canada, 
the UK, and US have the most experience with CED applied to devices; Germany 
and The Netherlands have both recently introduced new CED policies for devices 
and procedures. Devices that have undergone CED in these jurisdictions include 
ICDs, stents, TAVI, laparoscopic surgery, and spinal cord stimulators. While there 
are distinct differences in the national approaches to CED, common challenges 
were identified: 1) establishing a clear framework for initiating, overseeing, and 
stopping CED studies, 2) identifying and applying appropriate study methods, 3) 
funding CED studies, 4) incentivizing studies, and 5) applying new evidence to 
inform coverage decisions. ConClusions: Devices are viable candidates for CED, 
given some of their unique characteristics and often uncertain evidence base at 
the time of coverage determination. However, improvements are needed, including 
enhanced clarity and predictability of CED selection criteria and processes, greater 
stakeholder collaboration, new models to fund studies and collect data, better 
incentives for physicians to engage in studies, and strengthened requirements 
for use of new evidence in coverage policies.
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objeCtives: During the last few years, there has been a steady increase in the 
number of implant registries, mainly in the field of arthroplasty. The benefit of a 
registry depends on its content and quality. However, there are no further data 
requirements, legal and financial issues or requirements for the organizational 
(p= 0.596). ConClusions: Time preference rates were aligned with those in the pub-
lished literature but the association between time preference and adherence was non-
significant in both primary and secondary analyses at an individual country level.
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objeCtives: Given economic pressure on UK National Health Service resources, it has 
been recommended that general practitioners prescribe more low-cost, generic drugs 
as opposed to high-cost, proprietary drugs when a substitution can be made without 
compromising patient care. One of the Better Care Better Value (BCBV) indicators of good 
prescribing practice proposed by the NHS Institute for Innovation and Improvement is 
an increase in the prescription of low-cost drugs for lipid modification. The objective of 
this analysis was to evaluate patterns of generic and proprietary prescribing of statins 
from 2007–2012 inclusive. Methods: Prescription Cost Analysis databases from data.
gov.uk were reviewed between 2007–2012. Data on the number of prescription items 
dispensed each year in the community in England for simvastatin and atorvastatin (as 
commonly-prescribed examples) were extracted, along with each drug’s preparation 
class: drugs prescribed and available generically, or drugs prescribed and dispensed by 
proprietary brand name. For both simvastatin and atorvastatin, the proportions of pre-
scription items in the different preparation classes were compared each year. Results: 
Proprietary simvastatin prescription items as a proportion of all simvastatin prescription 
items decreased each year, from 2.87% in 2007 (843,000 proprietary items) to 1.76% in 
2012 (752,000 items), representing a proportional decrease of 39% in the 6-year period 
assessed. Proprietary atorvastatin prescription items as a proportion of all atorvastatin 
prescription items were close to 100% between 2007–2011 (approximately 11 million 
proprietary items each year), but fell to 30.55% in 2012 (3.9 million items), coinciding 
with the expiry of atorvastatin’s patent in May 2012. ConClusions: In England, pre-
scribing of high-cost proprietary items for these two examples of lipid-modifying drugs 
has decreased since 2007, suggesting that the BCBV prescribing indicator for statins is 
being met. Such reductions, particularly as seen with atorvastatin in 2012, are likely to 
have a significant budget impact.
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objeCtives: Warfarin-treated patients with poor international normalized ratio 
(INR) control, measured with time in therapeutic range (TTR) or the standard 
deviation of transformed INR (SDTINR), have an increased risk for clinical events. 
To what extent only a short period with an altered INR control may influence out-
comes remains unknown. This study assessed the impact of transient periods of 
improved or worsened INR control on life expectancy and quality-adjusted life years 
(QALYs) among warfarin-treated patients with atrial fibrillation (AF) using both 
metrics. Methods: Warfarin-treated patients with AF, registered in the patient 
record system Journalia during years 1985-2000, were included. Information on all-
cause mortality was collected from the Cause of Death Register. Scenarios where 
patients were assumed to have a transiently altered INR control during 30 days 
were modeled statistically using hazard functions, and the impact on remaining life 
expectancy and QALYs was assessed. Results: When using SDTINR, a 70-year old 
man within the 2.5th worst INR control percentile was estimated to gain 10.8 days of 
life or 0.0168 QALYs from a 30-day improvement in INR control to that of an average 
70-year old man. Correspondingly, 15.5 days of life or 0.0196 QALYs would be lost if a 
70-year old man within the 2.5th best INR control percentile would have an average 
INR control during 30 days. The magnitudes were smaller when TTR was used to 
determine INR control. ConClusions: Even short periods of altered INR control 
is expected to have impact on life expectancy and QALYs among patients with AF.
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objeCtives: The majority of recent cost-effectiveness reviews concluded that 
computerized tomographic colonography (CTC) is not a cost-effective Colorectal 
Cancer (CRC) screening strategy yet. The objective of this review is to examine 
cost-effectiveness of CTC versus optical colonoscopy (COL) for CRC screening and 
identify the main drivers influencing cost-effectiveness due to the emergence of 
new research. Methods: A systematic review was conducted for cost-effectiveness 
studies comparing CTC and COL as a screening tool and providing outcomes in 
life-years saved, published between January 2006 and November 2012. The fol-
lowing databases were searched: PubMed, Science Direct, Cochrane Library and 
the York Centre for Reviews and Dissemination databases. The search methodol-
ogy was in line with PRISMA guidelines, including the use of the PICOS review 
system. Results: Nine studies were included in the review. There was consid-
erable heterogeneity in modelling complexity and methodology. Different model 
assumptions and inputs had large effects on resulting cost-effectiveness. The most 
important assumptions that influenced the cost-effectiveness of CTC and COL were 
related to CTC threshold-based reporting of polyps, CTC cost, CTC sensitivity for 
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objeCtives: Medicinal products where active substance, strength, form, or 
administration route have been modified differ from generic drugs as bioequiva-
lence cannot be demonstrated. In Europe, these ‘hybrid’ products have a clear 
registration pathway (Directive 2001/83/EC) requiring investment in pre-clinical 
and clinical trials. However; beyond the regulatory pathway, pricing and market 
access remains a national matter and few countries have specific methods to 
evaluate hybrids; both innovative- and generic-like prices may result. This study 
evaluated hybrid price differences and consequences for availability of hybrids 
across Europe. Methods: Using IMS MIDAS data and the HMA database of regis-
tered drugs, we screened 5,000 products to identify 40 hybrid products which were 
significantly differentiated from the reference product, launched between 2008-
2012 and analysed their prices and availability based on sales achieved, versus the 
reference product within and across 10 European markets. Results: Hybrid prices 
vary widely, but most frequently, generic rules are applied, limiting the interest of 
companies to make hybrids available across European markets. There is wide vari-
ation in availability of hybrids across markets, suggesting a decision not to launch 
in markets where prices are particularly unfavourable. Countries applying fixed 
generic pricing rules appear to have fewer hybrids. Yet where they are launched, 
hybrids are not classified as generics, so uptake is inhibited by non-substitution 
rules and prescribing quotas. ConClusions: The lack of clear evaluation criteria 
and pricing variability within and across countries are barriers to the availability 
of hybrid products to patients in Europe. To the degree that such products bet-
ter meet patient needs versus generic medicines, these barriers reduce patient 
welfare and prescriber choice. In a context where patient-oriented outcomes are 
increasingly seen as important, hybrid drugs have a role to play given their ability 
to improve administration, compliance, convenience and in some cases improve 
safety and efficacy. Consequently, clear rules for hybrid evaluation, pricing and 
access are desirable as they would improve patient care and reduce uncertainty 
for hybrid manufacturers.
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objeCtives: Coverage with evidence development (CED) in Sweden has become 
common over the last decade. It is considered as a tool to address uncertainty. The 
objective of this research is to assess from 2005 to 2012 CED in Sweden. Methods: 
We downloaded available CED from pricing authority (TLV) database, and extracted 
detailed information in an ad hoc grid developed for that purpose. The following 
information was extracted: date of product approval, name, indication, date of CED 
installation, end of CED, type of evidence to be generated, limitation of initial file 
supporting the need of additional evidences. Results: A total of 28 cases were 
retrieved covering 9 main disease areas. Eleven were for orphan drugs and 10 for 
Central nervous system (CNS) disorders including depression anxiety, epilepsy, 
pain, ADHD, schizophrenia, restless syndrome and Parkinson disease. Other were 
classified as follow, 5 for cardiovascular disorders, 3 oncology, 2 diabetes, 2 res-
piratory disorders and 5 others. The main drivers to request CED were weak cost-
effectiveness model (14 cases) driven by uncertainty about utility, patients benefit, 
transition probabilities, model structure etc. The second reason was low relevance 
of clinical evidence for clinical practice (8 cases), followed by long term efficacy 
extrapolation (5 cases) and others mainly related to comparative effectiveness, 
daily dosage, safety, target population, etc. (11 cases). For each CED more than one 
driver could be identified. Requirements were mostly real world evidence genera-
tion. ConClusions: CED in Sweden is likely to be driven more by uncertainty than 
drug prices due to low involvement of oncology, inflammation and other disease 
area where biologics are prescribed. Orphan drugs represent a leading target for CED 
as often little information is available at time of launch. Most CED are not finalised 
to assess the actual CED impact on long term coverage.
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objeCtives: Studies assessing the effectiveness of new Chronic Obstructive 
Pulmonary Disease (COPD) treatments commonly use disease-specific health-
related quality-of-life (HR-QoL) instruments such as the Clinical COPD Questionnaire 
(CCQ). However, for the economic evaluations, utility data is necessary. This study 
aims to develop a model to predict mean utility values for a group of COPD patients 
using CCQ data. Methods: We combined the data from two trials (RECODE and 
GO-AHEAD) including over 5000 observations with a broad range of disease sever-
ity. Data was randomly split into an estimation and validation sample. The overlap 
between the CCQ and EQ-5D was assessed using principal component and correla-
tion matrix analysis. Different types of models were created with increasing com-
plexity. We analysed the effect of using different observations of the same patients 
as unique observations and performed a sensitivity analysis using different EQ-5D 
value sets to estimate EQ-5D utilities. The external validity was tested with the 
dataset of the MARCH trial. Results: The principal component analyses showed 
a poor correlation of the dimension pain/discomfort with any of the CCQ items and 
the CCQ items cough and produce phlegm did not load onto any EQ-5D dimension. 
The model using ordinary least square with the individual CCQ items as dummy 
variables, controlled for sex, resulted in the best predicted performance. The mean 
procedure specified for implant registries in general. Therefore, the aim of this 
work is to identify quality criteria for the design and development of implant 
registries and to develop a minimal data set. Methods: The systematic literature 
search was performed in different databases (Pubmed, Medline, the Cochrane 
Library, Scopus, Embase as well as the CRD York database) and different jour-
nals. Results: Ten articles were identified that describe a general implant registry 
design and structure as well as 45 articles about the creation of specific registries. 
Most recommendations for the organization of implant registries could be found 
in the field of arthroplasty. To generalize the results, it can be said, that all regis-
tries have to deliver a minimal data set including prostheses, patient and surgical 
procedure details. The geographical area, length and periodicity of data collection, 
number of patients enrolled, the composition of the team as well as information 
about security and confidentiality of data should be reported. ConClusions: 
Well-structured registries are a cornerstone of the regulatory process of medical 
devices and a major tool for decison makers and managers. However, only a small 
number of papers that describe specific requirements for the construction of an 
implant registry could be identified. With the establishment of clear guidelines, the 
outcomes of the implant registries can be fundamentally improved. This project 
is supported by the German Federal Ministry of Education and Research (BMBF) as 
part of the National Cluster of Excellence‚ Medical Technologies – Medical Valley 
EMN’ (Project grant No. 13EX1013B).
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objeCtives: The goal of this study is to analyse price differences triggered by 
the availability of biosimilars in developed pharmaceutical markets. Methods: 
1) Market availability of biosimilars in the following markets was studied: Australia, 
Canada, France, Germany, Italy, Spain, UK, Japan and the United States. Biosimilars 
were selected based on their availability in these markets, and 2) Ex-factory price 
differences at launch between biosimilars and their originator counterparts were 
analysed. Results: Price differences between biosimilars and their originator 
counterpart were on average 25%. One exception aside, biosimilars always trigger 
double digit price differences. Given the limited availability of biosimilars, it is too 
soon to say if results will be consistent over time. Nevertheless, the general trend 
shows that large price differences are observed in Canada and the US (at least 
35%) and lower trends in Australia (around 16%). In the top 5 European pharma-
ceutical markets, price differences range between 17% and 30%. In Japan, price 
differences are also high, 29% on average. It should also be highlighted that the 
market entry of biosimilars does not always trigger the price of their originator 
to drop; in rare occasions only are their prices brought into line. ConClusions: 
Owing to the fact that biologic drugs are commonly expensive and with double 
digit price differences between biosimilars and their originator counterpart, the 
market entry of biosimilars should enable governments to generate significant 
savings. Nevertheless, a limited number of biosimilars are at the moment approved 
and in addition to the fact that no legislation is in place in the US, there is no sign 
of improvement in the other countries studied. As a consequence, savings will 
only be achieved if governments incentivise the development of biosimilars as 
well as their use.
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objeCtives: In the context of ever increasing demand and expenditure for health 
services it is important to identify policies which may maximise efficiency. Often, 
pharmaceuticals (approximately 20% of total health care expenditure) are a pri-
mary target for achieving efficiencies. This study aims to study the efficiency 
of pharmaceutical control policies. Methods: Data on pharmaceutical policies 
and markets across 65 countries were collected from the published literature, 
with emphasis on the following domains: pricing, reimbursement, dispensing, 
expenditure and demand control. In each domain, policies were classified and 
through a multiple-country expert survey were graded for the degree of regu-
lation. Countries were clustered according to their policy mix. Principal com-
ponent analysis (PCA) served to group policies into three components: pricing 
policies, reimbursement policies and demand and cost control policies. Regression 
analysis with pharmaceutical expenditure as % of GDP as dependent variable 
was used to analyse the efficiency of policies. Independent variables were life 
expectancy, dependency ratios, mortality rates, GDP per capita and health system 
type. Results: Spearman correlation coefficients indicated that there was no 
statistically significant association between total pharmaceutical expenditure 
as % of GDP and regulation in the coverage, pricing, reimbursement, dispensing 
policy and system type. A statistically significant positive correlation between 
regulation and indirect price and cost controls (0.334, p= 0.028) and demand con-
trols (0.333, p= 0.019) implies that more regulation in these domains is associated 
with higher expenditure. Following the PCA, regulation in demand control policies 
was associated with higher expenditure (0.342, p= 0.025) and the same applies 
for the aggregate of the components (0.314, p= 0.040). In regression analysis the 
coefficients (p-value) were pricing:-0.003(0.950), demand control:0.062(p= 0.067), 
reimbursement: -0.057(0.439), mortality: 0.001(0.414), Life Expectancy: 0.062(0.474), 
elderly ratio: 0.689(0.774), GDP-per-capita: -1.788(0.017). ConClusions: A variety 
of policies were developed recently to control pharmaceuticals. More regulation 
does not appear to increase efficiency or decrease expenditure.
